Angion Biomedica Corp. is a late-stage biopharmaceutical company. The Company focuses on discovery, development and commercialization of small molecule therapeutics to address acute organ injuries and fibrotic diseases. The Company’s lead product candidate is ANG-3777. Its pipeline includes ANG-3070, rho kinase 2 (ROCK2), and CYP11B2. Its ANG-3777 is a hepatocyte growth factor (HGF) mimetic it is evaluating in multiple acute organ injuries and related indications, including...